SCHEMBL29470540

SCHEMBL29470540

COc1ccc([C@H](NC(=O)OCC2c3ccccc3-c3ccccc32)c2ccc(OCC(=O)O)cc2)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ CASP3 P42574 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MDM2 Q00987 1/20 0.43
▸ THRA P10827 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ PTPN1 P18031 2/20 0.41
▸ FABP5 Q01469 1/20 0.41
▸ MDM4 O15151 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1000962 1.00 KMT2A (0.45) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL1745934 1.00 KMT2A (0.45) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL31146900 1.00 KMT2A (0.45) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL3367289 1.00 KMT2A (0.45) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL29368397 1.00 KMT2A (0.45) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL14416300 0.93 KMT2A (0.42) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL13183250 0.92 KMT2A (0.42) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL30558303 0.92 KMT2A (0.42) KMT2AMEN1CASP3NPC1RAB9A
SCHEMBL12873284 0.92 LMNA (0.46) KMT2AMEN1CASP3MDM2FABP5
SCHEMBL12555211 0.92 KMT2A (0.47) KMT2AMEN1CASP3MDM2FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727655-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 — — EP disclosed
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 — — EP disclosed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 — — EP disclosed
WO-2025245244-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 — — WO disclosed
WO-2025245294-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 — — WO disclosed
WO-2025123059-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS ENDEVICA BIO, INC. (US) 2025-06-12 — — WO disclosed
WO-2025123055-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-06-12 — — WO disclosed
WO-2025123056-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS ENDEVICA BIO, INC. (US) 2025-06-12 — — WO disclosed
EP-4565258-A2 COMPOSITIONS FOR THE TREATMENT OF DISEASE Sightstream Biotherapeutics, Inc. (US) 2025-06-11 — — EP disclosed
WO-2024259132-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC. (US) 2024-12-19 — — WO disclosed
WO-2024259147-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC. (US) 2024-12-19 — — WO disclosed
WO-2024259115-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC. (US) 2024-12-19 — — WO disclosed
WO-2024030950-A2 COMPOSITIONS FOR THE TREATMENT OF DISEASE SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) 2024-02-08 — — WO disclosed
Send feedback